![Dana Pizzuti](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dana Pizzuti
No open positions remaining
Net worth: 154 180 $ as of 2026-05-30
Profile
Dana Pizzuti worked at Gilead Sciences, Inc. as Vice President-Regulatory Affairs from 2007 to 2017.
Served as SVP-Regulatory Affairs & Quality at Rigel Pharmaceuticals, Inc. from 2017 to 2019.
Held the position of SVP-Regulatory Affairs & Quality at Theravance Biopharma, Inc. in 2019.
Worked as Vice President-Global Regulatory Affairs at Ascendis Pharma A in 2019 and later as Chief Medical Officer there from 2020 to 2022.
Held roles at Johnson & Johnson as Vice President-Global Regulatory Affairs and at Bristol-Myers Squibb AB as Vice President-Global Pharmacovigilance & Labeling.
Currently Chief Medical & Development Officer at Crinetics Pharmaceuticals, Inc. from 2022 to 2025.
Education includes undergraduate studies at Yale University and a doctorate from New York University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-19 | 4,337 ( 0% ) | 154 180 $ | 2026-05-30 |
Former positions of Dana Pizzuti
| Companies | Position | End |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2025-12-30 |
| ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | 2022-08-31 |
| ASCENDIS PHARMA A/S | General Counsel | 2019-11-30 |
| THERAVANCE BIOPHARMA, INC. | Corporate Officer/Principal | 2019-06-30 |
| RIGEL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2019-02-28 |
Training of Dana Pizzuti
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
59
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Rigel Pharmaceuticals, Inc.
 Rigel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which discovers, develops and provides novel small-molecule drugs | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Bristol-Myers Squibb AB
 Bristol-Myers Squibb AB Medical DistributorsDistribution Services Wholesales medical equipment and pharmacy | Distribution Services |
Theravance Biopharma, Inc.
 Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
New York University School of Medicine
 New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Crinetics Pharmaceuticals, Inc.
 Crinetics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics for endocrine-related diseases | Health Technology |
- Stock Market
- Insiders
- Dana Pizzuti
